Therapeutic Area	Action	Drug Class	Drug	Clinical Annotation	Gene	Phenotype	ICD Codes	Conditions	Source	LOE
Anesthesiology	DOWN/DOWN	General Anesthetics	Ketamine (Ketalar?), Propofol (Diprivan?)	DECREASE DOSE due to decreased drug clearance/DECREASE DOSE due to decreased drug clearance	CYP2B6	G516T Heterozygous/G516T Homozygous			PGKB	2, 2
Anesthesiology	SLOW/SLOW	Local Anesthetics	Lidocaine (Lidoderm?), Ropivacaine (Naropin?)	USE CAUTION due to increased risk of drug toxicity/USE CAUTION due to increased risk for loss of efficacy	CYP1A2	Poor Metabolizer/Ultrarapid Metabolizer	R25, R29, M62, M72, M79	pain	Literature	3, 3
Anesthesiology	STOP	Local Anesthetics	Lidocaine/Prilocaine (Emla?)	CONSIDER ALTERNATIVES due to high susceptibility to drug-induced methemoglobinemia	G6PD	G6PD Deficiency	R25, R29, M62, M72, M79	pain	FDA	1
Anesthesiology	GO	Sedatives	Dexmedetomidine (Precedex?)	NORMAL DOSE may have an increased sedative response 	ADRA2A	rs1800544 CC genotype			PGKB	2
Cardiology	SLOW/SLOW	ACE Inhibitors	Benazepril (Lotensin?), Perindopril (Aceon?)	USE CAUTION due to reduced response/USE CAUTION due to reduced response	ACE	Heterozygous ACE Insertion/Homozygous ACE Insertion	E08, E10, E11, E13, E78, I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	heart failure, chronic obstructive pulmonary disease, diabetes 	PGKB	2, 2
Cardiology	SLOW/SLOW	ACE Inhibitors	Captopril (Capoten?), Perindopril (Aceon?)	USE CAUTION due to increased major cardiovascular events rate/USE CAUTION due to increased major cardiovascular events rate	AGTR1	rs5186 AC genotype/rs5186 CC genotype	E08, E10, E11, E13, E78, I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	heart failure, chronic obstructive pulmonary disease, diabetes 	PGKB	2, 2
Cardiology	SLOW	ACE Inhibitors	Captopril (Capoten?), Quinapril (Accupril?)	USE CAUTION due to reduced response	ACE	ACE Deletion	E08, E10, E11, E13, E78, I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	heart failure, chronic obstructive pulmonary disease, diabetes 	PGKB	2, 2
Cardiology	SLOW/SLOW	Angiotensin II Receptor Blockers	Candesartan (Atacand?)	USE CAUTION due to reduced response/USE CAUTION due to reduced response	AGTR1	rs5186 AC genotype/rs5186 CC genotype	E08, E10, E11, E13, E78, I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	hypertension, diabetes 	PGKB	2
Cardiology	SLOW/SLOW	Angiotensin II Receptor Blockers	Irbesartan (Avapro?)	USE CAUTION due to reduced response/USE CAUTION due to reduced response	ACE	ACE Deletion/Heterozygous ACE Insertion	E08, E10, E11, E13, E78, I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	hypertension, diabetes	PGKB	2
Cardiology	SLOW	Angiotensin II Receptor Blockers	Losartan (Cozaar?)	USE CAUTION due to reduced response	ABCB1	rs1045642 GG genotype	E08, E10, E11, E13, E78, I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	hypertension, diabetes	PGKB	2
Cardiology	SLOW	Angiotensin II Receptor Blockers	Losartan (Cozaar?)	USE CAUTION due to reduced response	AGTR1	rs5186 AA genotype	E08, E10, E11, E13, E78, I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	hypertension, diabetes	PGKB	2
Cardiology	SLOW	Antianginal Drugs	Ranolazine (Ranexa?)	USE CAUTION due to the risk of increased exposure to the drug leading to adverse events	CYP2D6	Poor Metabolizer	I20, I25	chronic angina, chest pain	EMA	2
Cardiology	SLOW/SLOW	Antiarrhythmic Drugs	Amiodarone (Cordarone?)	USE CAUTION due to increased risk of drug-induced ventricular arrhythmia and QT prolongation/USE CAUTION due to increased risk of drug-induced ventricular arrhythmia and QT prolongation 	NOS1AP	rs10800397 T Allele Carrier/rs10919035 T Allele Carrier	I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	angina, hypertension, heart attack, irregular heartbeats, heart failure	PGKB	2
Cardiology	STOP	Antiarrhythmic Drugs	Dronedarone (Multaq?)	CONSIDER ALTERNATIVES	CYP3A4	Poor Metabolizer	I47, I48, I49, R00, R01	heart rhythm disorders, ventricular arrhythmias, atrial fibrillation, supra-ventricular tachycardia, atrial tachycardia, AV nodal tachycardia, bypass tract tachycardias	EMA	2
Cardiology	SLOW/SLOW/SLOW	Antiarrhythmic Drugs	Digoxin (Lanoxin?)	USE CAUTION due to decreased metabolism/USE CAUTION due to decreased metabolism/USE CAUTION due to decreased metabolism	ABCB1	rs2032582 AA genotype/rs1045642 AA genotype/rs1045642 AG genotype	I47, I48, I49, R00, R01	heart rhythm disorders, ventricular arrhythmias, atrial fibrillation, supra-ventricular tachycardia, atrial tachycardia, AV nodal tachycardia, bypass tract tachycardias	PGKB	2
Cardiology	DOWN/DOWN/STOP	Antiarrhythmic Drugs	Flecainide (Tambocor?)	DECREASE DOSE by 50%/DECREASE DOSE by 25%/CONSIDER ALTERNATIVES (e.g., sotalol, disopyramide, quinidine, amiodarone)	CYP2D6	Poor Metabolizer/Intermediate Metabolizer/Ultrarapid Metabolizer	I47, I48, I49, R00, R01	heart rhythm disorders, ventricular arrhythmias, atrial fibrillation, supra-ventricular tachycardia, atrial tachycardia, AV nodal tachycardia, bypass tract tachycardias	DPWG	2
Cardiology	DOWN/STOP/STOP	Antiarrhythmic Drugs	Propafenone (Rythmol?)	DECREASE DOSE by 70% and avoid simultaneous use with a CYP3A4 inhibitor/CONSIDER ALTERNATIVES (e.g., sotalol, disopyramide, quinidine, amiodarone)/CONSIDER ALTERNATIVES (e.g., sotalol, disopyramide, quinidine, amiodarone)	CYP2D6	Poor Metabolizer/Intermediate Metabolizer/Ultrarapid Metabolizer	I47, I48, I49, R00, R01	heart rhythm disorders, ventricular arrhythmias, atrial fibrillation, supra-ventricular tachycardia, atrial tachycardia, AV nodal tachycardia, bypass tract tachycardias	FDA, DPWG	1
Cardiology	UP/UP	Anticoagulants	Phenprocoumon (Marcoumar?)	INCREASE DOSE/INCREASE DOSE	CYP4F2	Poor Metabolizer/Intermediate Metabolizer	G45, I20, I21, I24, I25, I26, I42, I47, I48, I49, I50, I65, I67, I70, I73, I82	heart attacks, strokes, and blood clots in veins and arteries	PGKB	2
Cardiology	SLOW	Anticoagulants	Rivaroxaban (Xarelto?)	USE CAUTION due to increased bleeding risk	CYP3A4	Poor Metabolizer	G45, I20, I21, I24, I25, I26, I42, I47, I48, I49, I50, I65, I67, I70, I73, I82	heart attacks, strokes, and blood clots in veins and arteries	Literature	3
Cardiology	SLOW	Anticoagulants	Warfarin (Coumadin?)	Genetic testing required	CYP2C9	Poor Metabolizer/Intermediate Metabolizer	G45, I20, I21, I24, I25, I26, I42, I47, I48, I49, I50, I65, I67, I70, I73, I82	heart attacks, strokes, and blood clots in veins and arteries	FDA, CPIC, HCSC	1
Cardiology	SLOW	Anticoagulants	Warfarin (Coumadin?)	Genetic testing required	VKORC1	 rs9923231 A Allele Carrier	G45, I20, I21, I24, I25, I26, I42, I47, I48, I49, I50, I65, I67, I70, I73, I82	heart attacks, strokes, and blood clots in veins and arteries	FDA, CPIC, HCSC	1
Cardiology	SLOW/SLOW	Antilipemic Agents (Statins)	Atorvastatin (Lipitor?)	USE CAUTION due to higher risk of developing myalgia/USE CAUTION due to higher risk of developing myalgia	ABCB1	rs1045642 AA genotype/rs1045642 AG genotype	E78, I10, I11, I12, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	high cholesterol, high triglycerides, stroke, heart attack, other heart complications, coronary heart disease 	PGKB	2
Cardiology	GO	Antilipemic Agents (Statins)	Atorvastatin (Lipitor?)	NORMAL DOSE may have a better response 	APOE	E2 Carrier	E78, I10, I11, I12, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	high cholesterol, high triglycerides, stroke, heart attack, other heart complications, coronary heart disease 	PGKB	2
Cardiology	SLOW	Antilipemic Agents (Statins)	Atorvastatin (Lipitor?), Lovastatin (Mevacor?), Rosuvastatin (Crestor?)	USE CAUTION due to impaired efficacy	CYP3A5	High Expresser	E78, I10, I11, I12, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	high cholesterol, high triglycerides, stroke, heart attack, other heart complications, coronary heart disease 	PGKB	2, 2, 2
Cardiology	DOWN	Antilipemic Agents (Statins)	Atorvastatin (Lipitor?), Pitavastatin (Livalo?), Pravastatin (Pravachol?), Rosuvastatin (Crestor?)	DECREASE DOSE	SLCO1B1	Low Activity	E78, I10, I11, I12, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	high cholesterol, high triglycerides, stroke, heart attack, other heart complications, coronary heart disease 	CPIC	2, 2, 2, 2
Cardiology	SLOW	Antilipemic Agents (Statins)	Atorvastatin (Lipitor?), Pravastatin (Pravachol?)	USE CAUTION due to poorer response to statin treatment with decreased risk for adverse cardiovascular events 	KIF6	rs20455 AA genotype	E78, I10, I11, I12, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	high cholesterol, high triglycerides, stroke, heart attack, other heart complications, coronary heart disease 	PGKB	2, 2
Cardiology	SLOW/SLOW	Antilipemic Agents (Statins)	Lovastatin (Mevacor?)	USE CAUTION due to decreased response/USE CAUTION due to decreased response	LDLR	rs688 CC Genotype/rs688 CT Genotype	E78, I10, I11, I12, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	high cholesterol, high triglycerides, stroke, heart attack, other heart complications, coronary heart disease 	PGKB	3
Cardiology	SLOW/SLOW	Antilipemic Agents (Statins)	Fluvastatin (Lescol?)	USE CAUTION due to reduced response/USE CAUTION due to reduced response	ACE	Heterozygous ACE Insertion/Homozygous ACE Insertion	E78, I10, I11, I12, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	high cholesterol, high triglycerides, stroke, heart attack, other heart complications, coronary heart disease 	PGKB	2
Cardiology	SLOW/SLOW/SLOW	Antilipemic Agents (Statins)	Simvastatin (Zocor?)	USE CAUTION due to reduced response and increased risk of developing myalgia /USE CAUTION due to higher risk of developing myalgia/USE CAUTION due to higher risk of developing myalgia	ABCB1	rs2032582 CC genotype/rs1045642 AG genotype/rs1045642 GG genotype	E78, I10, I11, I12, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	high cholesterol, high triglycerides, stroke, heart attack, other heart complications, coronary heart disease 	PGKB	2
Cardiology	STOP DOWN/STOP DOWN	Antilipemic Agents (Statins)	Simvastatin (Zocor?)	CONSIDER ALTERNATIVES or DECREASE DOSE to 20mg daily/CONSIDER ALTERNATIVES or DECREASE DOSE to 20mg daily	SLCO1B1	Low Activity/Intermediate Activity	E78, I10, I11, I12, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	high cholesterol, high triglycerides, stroke, heart attack, other heart complications, coronary heart disease 	CPIC	2
Cardiology	SLOW/SLOW	Antilipemic Agents	Fenofibrate (Tricor?)	USE CAUTION due to decreased response/USE CAUTION due to decreased response	APOB	rs676210 GG Genotype/rs676210 GA Genotype	E78, I10, I11, I12, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	high cholesterol, high triglycerides, stroke, heart attack, other heart complications, coronary heart disease 	PGKB	3
Cardiology	GO	Antilipemic Agents	Fenofibrate (Tricor?)	NORMAL DOSE may have an increased response 	APOE	E2 Carrier	E78, I10, I11, I12, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	high cholesterol, high triglycerides, stroke, heart attack, other heart complications, coronary heart disease 	PGKB	2
Cardiology	STOP/STOP	Antiplatelets	Clopidogrel (Plavix?)	CONSIDER ALTERNATIVES (if no contraindication e.g., prasugrel, ticagrelor)/CONSIDER ALTERNATIVES (if no contraindication e.g., prasugrel, ticagrelor)	CYP2C19	Poor Metabolizer/Intermediate Metabolizer	G45, I20, I21, I24, I25, I42, I47, I48, I49, I50, I65, I67, I70, I73	heart attack, stroke, heart disorders, blood vessels disorders;	FDA, EMA, PMDA, HCSC, CPIC, DPWG	1
Cardiology	GO/GO	Antiplatelets	Ticagrelor (Brilinta?)	NORMAL DOSE/NORMAL DOSE	CYP2C19	Poor Metabolizer/Intermediate Metabolizer	G45, I20, I21, I24, I25, I42, I47, I48, I49, I50, I65, I67, I70, I73	heart attack, stroke, heart disorders, blood vessels disorders;	FDA, EMA	1
Cardiology	SLOW/SLOW	Beta Blockers	Atenolol (Tenormin?)	USE CAUTION due to decreased drug response/USE CAUTION due to decreased drug response	ADRA2A	rs1800545 GA genotype/rs1800545 AA genotype	I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	angina, hypertension, heart attack, irregular heartbeats, heart failure	PGKB	2
Cardiology	SLOW	Beta Blockers	Carvedilol (Coreg?)	USE CAUTION due to higher plasma concentrations of R(+)-carvedilol and higher rate of dizziness	CYP2D6	Poor Metabolizer	I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	angina, hypertension, heart attack, irregular heartbeats, heart failure	FDA, HCSC	1
Cardiology	STOP DOWN/STOP DOWN/STOP UP	Beta Blockers	Metoprolol (Lopressor?)	CONSIDER ALTERNATIVES (e.g., bisoprolol, carvedilol) or DECREASE DOSE by 75% due to heart failure caused by the decreased drug cardioselectivity/CONSIDER ALTERNATIVES (e.g., bisoprolol, carvedilol) or DECREASE DOSE by 50% due to heart failure caused by the decreased drug cardioselectivity/CONSIDER ALTERNATIVES (e.g., bisoprolol, carvedilol) or INCREASE DOSE by 250% in response to efficacy and ADE	CYP2D6	Poor Metabolizer/Intermediate Metabolizer/Ultrarapid Metabolizer	I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	angina, hypertension, heart attack, irregular heartbeats, heart failure	FDA, DPWG	1
Cardiology	GO	Beta Blockers	Nebivolol (Bystolic?), Propranolol (Inderal LA?)	NORMAL DOSE	CYP2D6	Poor Metabolizer	I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	angina, hypertension, heart attack, irregular heartbeats, heart failure	FDA	1, 1
Cardiology	SLOW	Calcium Channel Blockers	Amlodipine (Norvasc?), Diltiazem (Cardizem?), Felodipine (Plendil?), Lercanidipine (Zanidip?), Nisoldipine (Sular?)	USE CAUTION due to significant increase in drug exposure and therefore clinical monitoring may be required	CYP3A4	Poor Metabolizer	I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	angina, hypertension, heart attack, irregular heartbeats, heart failure	Literature	2, 3, 3, 3, 3
Cardiology	SLOW/SLOW	Calcium Channel Blockers	Amlodipine (Norvasc?), Nifedipine (Adalat?)	USE CAUTION due to increased risk for QTc prolongation/USE CAUTION due to increased risk for QTc prolongation 	NOS1AP	rs10494366 GG genotype/rs10494366 GT genotype	I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	angina, hypertension, heart attack, irregular heartbeats, heart failure	PGKB	2, 3
Cardiology	SLOW/SLOW	Calcium Channel Blockers	Nitrendipine (Nitrepin?)	USE CAUTION due to reduced response/USE CAUTION due to reduced response	AGTR1	rs5186 AC genotype/rs5186 CC genotype	I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	angina, hypertension, heart attack, irregular heartbeats, heart failure	PGKB	2
Cardiology	SLOW	Calcium Channel Blockers	Verapamil (Calan?)	USE CAUTION due to increased risk for QTc prolongation 	NOS1AP	rs10494366 GG genotype	I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	angina, hypertension, heart attack, irregular heartbeats, heart failure	PGKB	2
Cardiology	SLOW	Diuretics	Bumetanide (Bumex?), Furosemide (Lasix?), Hydrochlorothiazide (Microzide?), Torsemide (Demadex?)	USE CAUTION due to reduced response	ACE	Homozygous ACE Insertion	E78, I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	hypertension	PGKB	2, 2, 2, 2
Cardiology	GO	Diuretics	Hydrochlorothiazide (Microzide?)	NORMAL DOSE may have a decreased risk of developing diabetes	AGTR1	rs5186 CC genotype	E78, I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	hypertension	PGKB	2
Cardiology	GO	Diuretics	Spironolactone (Aldactone?)	NORMAL DOSE may be associated with greater symptom improvement 	ACE	Homozygous ACE Insertion	E78, I10, I11, I12, I15, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	hypertension	PGKB	2
Cardiology	SLOW	Miscellaneous Cardiovascular Agents	Ivabradine (Corlanor?)	USE CAUTION due to significant increase in drug exposure and therefore clinical monitoring may be required	CYP3A4	Poor Metabolizer	I20, I25	chronic angina, chest pain	EMA	2
Cardiology	SLOW	Phosphodiesterase Inhibitors	Cilostazol (Pletal?)	USE CAUTION due to decrease in drug clearance	CYP3A5	Non Expresser	I73	Peripheral vascular disease (pvd), Intermittent claudication, Vascular Graft Occlusion	PGKB	2
Cardiology	SLOW/SLOW	Vasodilators	Hydralazine	USE CAUTION due to decreased drug response/USE CAUTION due to decreased drug response	NAT2	Rapid Acetylator/Intermediate Acetylator	E78, I10, I11, I12, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	hypertension	FDA	1
Cardiology	GO	Vasodilators	Nitroprusside (Nitropress?)	NORMAL DOSE may experience greater vasodilation 	ACE	Homozygous ACE Insertion	E78, I10, I11, I12, I20, I21, I24, I25, I42, I47, I48, I49, I50, I51, I70	hypertension	PGKB	2
Dentistry	SLOW	Cholinergic Agonists	Cevimeline (Evoxac?)	USE CAUTION due to higher risk of adverse events	CYP2D6	Poor Metabolizer		dry mouth	FDA	1
Endocrinology	SLOW/SLOW	Biguanides	Metformin (Glucophage?)	USE CAUTION due to decreased drug response/USE CAUTION due to decreased drug response	ATM	rs11212617 AA genotype/rs11212617 AC genotype	E08, E09, E10, E11, E13	diabetes	PGKB	2
Endocrinology	DOWN/STOP	Endocrine Enzyme Inhibitors	Eliglustat (Cerdelga?)	DECREASE DOSE by 50% to 84mg once daily/CONSIDER ALTERNATIVES due to adequate drug concentrations won't be achieved for a therapeutic effect	CYP2D6	Poor Metabolizer/Ultrarapid Metabolizer	E75	Gaucher disease type 1	FDA, EMA, PMDA	1
Endocrinology	STOP	Sulfonylureas	Chlorpropamide (Diabinese?), Glimepiride (Amaryl?), Glipizide (Glucotrol?), Glyburide (Glynase?), Tolbutamide	CONSIDER ALTERNATIVES	G6PD	G6PD Deficiency	E08, E09, E10, E11, E13	diabetes	FDA, EMA	1, 1, 1, 1, 3
Endocrinology	SLOW	Thiazolidinediones	Pioglitazone (Actos?)	USE CAUTION due to higher risk of side effects caused by decreased drug metabolism 	CYP2C8	Allele 3 Carrier	E08, E09, E10, E11, E13	diabetes	PGKB	2
Endocrinology	SLOW	Thiazolidinediones	Rosiglitazone (Avandia?)	USE CAUTION due to decreased response caused by increased drug metabolism 	CYP2C8	Allele 3 Carrier	E08, E09, E10, E11, E13	diabetes	PGKB	2
Gastroenterology	GO/GO/GO/GO	Histamine H2 Antagonists	Famotidine (Pepcid?)	NORMAL DOSE/NORMAL DOSE/NORMAL DOSE/NORMAL DOSE	CYP2C19	Poor Metabolizer/Intermediate Metabolizer/Rapid Metabolizer/Ultrarapid Metabolizer	K21, K29, K31	heartburn, gastroesophageal reflux disease (GERD), and esophageal damage	Literature	3
Gastroenterology	SLOW	Monoclonal Antibody	Adalimumab (Humira?)	USE CAUTION due to decreased response	HFE	rs2071303 TT Genotype	K50	Crohn's disease	PGKB	3
Gastroenterology	SLOW	Osmotic Laxatives 	Ascorbic Acid (MoviPrep?)	USE CAUTION due to a risk of hemolytic anemia	G6PD	G6PD Deficiency	K59	Constipation	FDA, PMDA, HCSC	1
Gastroenterology	UP/UP/SLOW/SLOW	Proton Pump Inhibitors (PPIs)	Dexlansoprazole (Dexilant?), Esomeprazole (Nexium?), Lansoprazole (Prevacid?), Omeprazole (Prilosec?), Pantoprazole (Protonix?), Rabeprazole (Aciphex?)	INCREASE DOSE by 50-200% and then adjusted to achieve a favorable clinical response due to decreased efficacy/INCREASE DOSE by 50-200% and then adjusted to achieve a favorable clinical response due to decreased efficacy/USE CAUTION due to higher drug plasma levels/USE CAUTION due to higher drug plasma levels	CYP2C19	Ultrarapid Metabolizer/Rapid Metabolizer/Poor Metabolizer/Intermediate Metabolizer	K21, K29, K31	heartburn, gastroesophageal reflux disease (GERD), and esophageal damage	FDA, EMA, HCSC, DPWG	1, 1, 1, 1, 1, 1
Gynecology	STOP SLOW	Hormonal Contraceptives	Ethinyl Estradiol/Norelgestromin (Ortho Evra?)	CONSIDER ALTERNATIVES (e.g., copper intrauterine device, progestin-only contraceptive) with presence of positive family history of thrombotic events or USE CAUTION by avoid additional risk factors (e.g., obesity, smoking) with absence of positive family history of thrombotic events	F5	Factor V Leiden Carrier			EMA, DPWG	1
Gynecology	SLOW	Hormones	Oral-Contraceptive	USE CAUTION due to an increased risk for deep vein thrombosis 	F2	F2 G20210A Mutation			PGKB	2
Gynecology	SLOW	Mixed 5-HT1A Agonists/5-HT2A Antagonists	Flibanserin (Addyi?)	USE CAUTION due to an increased risk for ADRs such as syncope 	CYP2C19	Poor Metabolizer	F52	decreased sexual desire in women	FDA	1
Hematology	SLOW	Colony Stimulating Factors	Eltrombopag (Promacta?)	USE CAUTION due to the potential for an increased risk of thromboembolism 	F5	Factor V Leiden Carrier			FDA, EMA	1
Immunology	SLOW	5-Aminosalicylic Acid Derivatives	Sulfasalazine (Azulfidine?)	USE CAUTION due to a risk of hemolytic anemia	G6PD	G6PD Deficiency	K51, M05, M06	ulcerative colitis, rheumatoid arthritis	FDA	1
Immunology	SLOW	Antigout Agents	Lesinurad (Zurampic?)	USE CAUTION due to increased drug exposure 	CYP2C9	Poor Metabolizer	M10	Gout	FDA	1
Immunology	SLOW	Antirheumatic Immunosuppressants	Methotrexate (Trexall?)	USE CAUTION due to an increased risk for gastrointestinal toxicities and a decreased response to drug 	ITPA	rs1127354 A Allele Carrier 	M06, M12, M13	Rheumatoid arthritis	PGKB	2
Immunology	UP/UP	Immunosuppressant Agents	Cyclosporine (Gengraf?), Sirolimus (Rapamune?)	INCREASE DOSE/INCREASE DOSE	CYP3A5	High Expresser/Expresser	D89	Graft-versus-host disease, organ rejection	PGKB	2, 2
Immunology	UP/UP	Immunosuppressant Agents	Tacrolimus (Prograf?)	INCREASE DOSE/INCREASE DOSE	CYP3A4	Poor Metabolizer/Intermediate Metabolizer	D89	Graft-versus-host disease, organ rejection	PGKB	2
Immunology	UP/UP	Immunosuppressant Agents	Tacrolimus (Prograf?)	INCREASE DOSE with 1.5 to 2 times recommended starting dose not exceed 0.3mg per kg per day/INCREASE DOSE with 1.5 to 2 times recommended starting dose not exceed 0.3mg per kg per day	CYP3A5	High Expresser/Expresser	D89	Graft-versus-host disease, organ rejection	CPIC	2
Immunology	STOP DOWN/DOWN	Immunosuppressive Drugs	Azathioprine (Imuran?)	CONSIDER ALTERNATIVES or DECREASE DOSE by 90% of full dose then titrate based on tolerance/DECREASE DOSE by 30-70% of full dose and titrate based on tolerance 	TPMT	Poor Metabolizer/Intermediate Metabolizer	D69, G35, M06, M12, M13	Crohn's disease, Ulcerative colitis, Systemic lupus erythematosus, Rheumatoid arthritis, Multiple sclerosis, Idiopathic thrombocytopenic purpura, Hashimoto's encephalopathy	FDA, CPIC, DPWG	1
Immunology	SLOW/SLOW	Systemic Corticosteroids	Methylprednisolone (Medrol?), Prednisolone (Orapred?), Prednisone (Deltasone?)	USE CAUTION due to increased risk of Osteonecrosis/USE CAUTION due to increased risk of Osteonecrosis	ABCB1	rs1045642 AG genotype/rs1045642 GG genotype	G35	inflammation, severe allergies, flares of chronic illnesses, Multiple sclerosis	PGKB	2, 2, 2
Immunology	SLOW	Urate-Oxidase (Recombinent)	Pegloticase (Krystexxa?)	USE CAUTION due to the risk of hemolysis and methemoglobinemia	G6PD	G6PD Deficiency	M10	Gout	FDA, EMA	1
Immunology	SLOW	Uricosuric Agents	Probenecid	USE CAUTION due to the risk of hemolysis and methemoglobinemia	G6PD	G6PD Deficiency	M10	Gout	FDA, EMA	1
Immunology	STOP	Xanthine Oxidase Inhibitors	Allopurinol (Zyloprim?)	CONSIDER ALTERNATIVES due to significantly increased risk of drug-induced SCAR	HLA-B	HLA-B*5801 Allele Carrier	M10	Gout	CPIC, PMDA	1
Infectious Diseases	STOP/STOP/STOP	Antifungal Drugs	Voriconazole (Vfend?)	CONSIDER ALTERNATIVES (e.g., isavuconazole, liposomal amphotericin B, posaconazole)/CONSIDER ALTERNATIVES (e.g., isavuconazole, liposomal amphotericin B, posaconazole)/CONSIDER ALTERNATIVES (e.g., isavuconazole, liposomal amphotericin B, posaconazole)	CYP2C19	Poor Metabolizer/Rapid Metabolizer/Ultrarapid Metabolizer	B37	serious infections of Aspergillus fumigatu, Candida, Scedosporium, Fusarium and other species	FDA, EMA, PMDA, HCSC, CPIC, DPWG	1
Infectious Diseases	SLOW	Antihepaciviral Drugs	Boceprevir (Victrelis?), Ledipasvir/Sofosbuvir (Harvoni?), Peginterferon alfa-2b (PegIntron?), Ribavirin (Copegus?), Telaprevir (Incivo?)	USE CAUTION due to decreased response and increased likelihood of relapse	IFNL3	Unfavorable Response Genotype 	B18, B19, K76	HCV	FDA, EMA, CPIC, DPWG	1, 1, 1, 2, 1
Infectious Diseases	SLOW	Antihepaciviral Drugs	Boceprevir (Victrelis?), Peginterferon alfa-2b (PegIntron?), Ribavirin (Copegus?), Telaprevir (Incivo?)	USE CAUTION due to increased risk of ribavirin-induced hemolytic anemia	ITPA	Non-protective Wild Type	B18, B19, K76	HCV	Literature	3, 2, 2, 3
Infectious Diseases	SLOW	Antimalarial Drugs	Chloroquine (Aralen?), Primaquine Phosphate (Primaquine?), Quinine (Qualaquin?)	USE CAUTION due to high risk for hemolysis	G6PD	G6PD Deficiency	B50, B51, B52, B53, B54	Malaria	FDA, HCSC	1, 1, 1
Infectious Diseases	STOP	Antiretroviral Drugs	Abacavir (Ziagen?)	CONSIDER ALTERNATIVES due to significantly increased risk of abacavir hypersensitivity	HLA-B	HLA-B*5701 Allele Carrier	B20	HIV	FDA, EMA, PMDA, CPIC, DPWG	1
Infectious Diseases	STOP	Antiretroviral Drugs	Atazanavir (Reyataz?)	CONSIDER ALTERNATIVES due to high likelihood of drug discontinuation resulted from jaundice	UGT1A1	Homozygous *28 Allele Carrier	B20	HIV	CPIC	2
Infectious Diseases	SLOW	Antiretroviral Drugs	Dolutegravir (Tivicay?)	USE CAUTION due to higher potential for ADRs caused by decreased drug clearance	UGT1A1	Homozygous *28 Allele Carrier	B20	HIV	FDA	1
Infectious Diseases	SLOW/SLOW/SLOW	Antiretroviral Drugs	Efavirenz (Sustiva?), Nevirapine (Viramune?)	USE CAUTION due to higher potential for an increased frequency and severity of drug-associated adverse events/USE CAUTION due to higher potential for an increased frequency and severity of drug-associated adverse events/USE CAUTION due to higher potential for an increased frequency and severity of drug-associated adverse events	CYP2B6	G516T Homozygous/A785G Homozygous/T983C Homozygous	B20	HIV	EMA, HCSC	1, 2
Infectious Diseases	SLOW/SLOW	Antiretroviral Drugs	Lamivudine (Epivir?), Lopinavir/Ritonavir (Kaletra?), Zidovudine (Retrovir?)	USE CAUTION due to the increased risk of virological failure/USE CAUTION due to the increased risk of virological failure	ABCB1	rs1045642 AG genotype/rs1045642 GG genotype	B20	HIV	PGKB	2, 2, 2
Infectious Diseases	SLOW/SLOW	Antiretroviral Drugs	Nelfinavir (Viracept?)	USE CAUTION due to reduced therapeutic effect/USE CAUTION due to the increased risk of adverse effects caused by the increased drug plasma concentration	CYP2C19	Ultrarapid Metabolizer/Poor Metabolizer	B20	HIV	FDA, EMA	1
Infectious Diseases	SLOW	Antiretroviral Drugs	Nevirapine (Viramune?)	USE CAUTION due to increased risk of drug hepatotoxicity	ABCB1	rs1045642 GG genotype	B20	HIV	PGKB	2
Infectious Diseases	SLOW/SLOW	Antitubercular Agents	Ethambutol (Myambutol?), Isoniazid, Pyrazinamide (Rifater?), Rifampin (Rifadin?)	USE CAUTION due to increased risk of hepatotoxicity caused by decreased drug clearance/USE CAUTION due to increased risk of hepatotoxicity caused by decreased drug clearance	NAT2	Slow Acetylator/Intermediate Acetylator	B90	tuberculosis 	FDA	2, 1, 1, 1
Infectious Diseases	SLOW/SLOW	Lipopeptides 	Daptomycin (Cubicin?)	USE CAUTION due to decreased drug response/USE CAUTION due to decreased drug response	ABCB1	rs1045642 AG genotype/rs1045642 GG genotype			PGKB	2
Infectious Diseases	DOWN	Macrolides	Erythromycin/Sulfisoxazole (Pediazole?)	DECREASE DOSE due to a risk of hemolytic anemia	G6PD	G6PD Deficiency			FDA	1
Infectious Diseases	SLOW	Miscellaneous Antibiotics	Dapsone, Sulfamethoxazole/Trimethoprim (Bactrim?)	USE CAUTION due to an increased risk of hemolytic adverse reactions	G6PD	G6PD Deficiency		Leprosy, Dermatitis herpetiformis, Lepromatous leprosy	FDA	1, 1
Infectious Diseases	SLOW	Miscellaneous Antibiotics	Nalidixic Acid (Neggram?), Nitrofurantoin (Macrobid?)	USE CAUTION due to an association with hemolytic anemia	G6PD	G6PD Deficiency	N39, N41, R31		FDA	1, 1
Infectious Diseases	STOP	Topical Antibiotics 	Mafenide (Sulfamylon?)	CONSIDER ALTERNATIVES due to reported fatal ADR cases 	G6PD	G6PD Deficiency			FDA	1
Neurology	SLOW/SLOW/SLOW	Acetylcholinesterase Inhibitors 	Donepezil (Aricept?)	USE CAUTION due to decreased drug response caused by increased drug metabolism/USE CAUTION due to possible increased ADRs caused by decreased drug metabolism/USE CAUTION due to possible increased ADRs caused by decreased drug metabolism	CYP2D6	Ultrarapid Metabolizer/Poor Metabolizer/Intermediate Metabolizer	G30	Alzheimer, dementia	FDA	1
Neurology	SLOW	Acetylcholinesterase Inhibitors 	Galantamine (Razadyne?)	USE CAUTION the drug should be individually titrated to tolerability	CYP2D6	Poor Metabolizer	G30	Alzheimer, dementia	FDA, HCSC	1
Neurology	DOWN/SLOW	Anticonvulsant Drugs	Brivaracetam (Briviact?)	DECREASE DOSE/USE CAUTION due to possible increased ADRs	CYP2C19	Poor Metabolizer/Intermediate Metabolizer	F63, G40, M79, R29, R52, R53, R56	seizures, convulsion, epilepsy	FDA, HCSC	1
Neurology	GO	Anticonvulsant Drugs	Carbamazepine (Tegretol?), Lamotrigine (Lamictal?), Oxcarbazepine (Trileptal?), Phenytoin (Dilantin?), Topiramate (Topamax?)	NORMAL DOSE may have a decreased risk of drug resistance 	SCN2A	rs2304016 GG genotype	F50, F63, G40, M79, R29, R52, R53, R56	seizures, convulsion, epilepsy, eating disorder	PGKB	2, 2, 2, 2, 2
Neurology	STOP	Anticonvulsant Drugs	Carbamazepine (Tegretol?), Phenytoin (Dilantin?)	CONSIDER ALTERNATIVES	HLA-B	HLA-B*1502 Allele Carrier	F63, G40, M79, R29, R52, R53, R56	seizures, convulsion, epilepsy	FDA, CPIC, PRO	1, 1
Neurology	SLOW	Anticonvulsant Drugs	Clobazam (Onfi?)	USE CAUTION with initial daily dose of 5 mg then titrate to daily 10~20 mg and further to a maximum daily 40 mg if tolerated	CYP2C19	Poor Metabolizer	F20, F25, F41, F51, G47	Anxiety, Agoraphobia, Panic disorder, Depressive Disorder	FDA	1
Neurology	GO	Anticonvulsant Drugs	Valproic Acid (Depakote?)	NORMAL DOSE may have lower weight gain 	ANKK1	A1 Homozygous	F20, F25, F31, F32, F33, F34, F84	Schizophrenia, Bipolar disorder, Dementia, Autism, Tourette syndrome	PGKB	2
Neurology	SLOW/SLOW	Anticonvulsant Drugs	Phenobarbital	USE CAUTION due to increased risk of drug resistance/USE CAUTION due to increased risk of drug resistance	ABCB1	rs1045642 AG genotype/rs1045642 GG genotype	G40, G47, M79, R29, R52, R53, R56	seizures, convulsion, epilepsy	PGKB	2
Neurology	SLOW	Antimigraine Agents	Eletriptan (Relpax?)	USE CAUTION due to the risk of increased exposure to the drug leading to adverse events	CYP3A4	Poor Metabolizer	G43	migraine	Literature	3
Neurology	SLOW/SLOW	Antimigraine Agents	Zolmitriptan (Zomig?)	USE CAUTION due to the increased risk of drug toxicity/USE CAUTION due to the increased risk for loss of efficacy	CYP1A2	Poor Metabolizer/Ultrarapid Metabolizer	G43	migraine	Literature	3
Neurology	DOWN	Central Monoamine-Depleting Agents	Tetrabenazine (Xenazine?)	DECREASE DOSE to 50mg daily with a maximum single dose of 25mg	CYP2D6	Poor Metabolizer			FDA	1
Neurology	SLOW	COMT Inhibitors	Entacapone (Comtan?)	USE CAUTION due to decreased response	COMT	MET Homozygous	G20	Parkinson	PGKB	2
Neurology	STOP/STOP	NMDA Receptor Antagonists	Dextromethorphan/Quinidine (Nuedexta?)	CONSIDER ALTERNATIVES due to risk of significant toxicity/CONSIDER ALTERNATIVES due to lower, potentially subtherapeutic effectiveness	CYP2D6	Poor Metabolizer/Ultrarapid Metabolizer	F48	pseudobulbar affect 	FDA, EMA	1
Oncology	SLOW	Alkylating Agents	Cyclophosphamide (Cytoxan?)	USE CAUTION due to worse outcome including overall survival and progression-free survival	NQO1	rs1800566 AA genotype	C16, C34, C50	stomach cancer, lung cancer, breast cancer	PGKB	2
Oncology	SLOW	Alkylating Agents	Cyclophosphamide (Cytoxan?)	USE CAUTION due to decreased drug response and increased severity of toxicity 	GSTP1	rs1695 GG genotype	C50	breast cancer	PGKB	2
Oncology	SLOW/SLOW	Alkylating Agents	Cyclophosphamide (Cytoxan?)	USE CAUTION due to poorer response and increased risk of toxicity/USE CAUTION due to poorer response and increased risk of toxicity	MTHFR	C677T Heterozygous Mutation/C677T Homozygous Mutation	C34, C50, C56, C81, C82, C83, C84, C85, C95	lung cancer, breast cancer, ovarian cancer, lymphoma, leukemia	PGKB	2
Oncology	SLOW/SLOW	Anthracyclines	Doxorubicin (Doxil?)	USE CAUTION due to the decreased survival rate/USE CAUTION due to the decreased survival rate	ABCB1	rs1045642 GG genotype/rs2032582 CC genotype	C90	Multiple Myeloma	PGKB	2
Oncology	SLOW	Anthracyclines	Doxorubicin (Doxil?)	USE CAUTION due to worse outcome including overall survival and progression-free survival	NQO1	rs1800566 AA genotype	C16, C34, C50	stomach cancer, lung cancer, breast cancer	PGKB	2
Oncology	SLOW	Anthracyclines	Epirubicin (Ellence?)	USE CAUTION due to decreased drug response and increased severity of toxicity 	GSTP1	rs1695 GG genotype	C50	breast cancer	PGKB	2
Oncology	SLOW	Anthracyclines	Epirubicin (Ellence?)	USE CAUTION due to worse outcome including overall survival and progression-free survival	NQO1	rs1800566 AA genotype	C16, C34, C50	stomach cancer, lung cancer, breast cancer	PGKB	2
Oncology	SLOW/SLOW	Antiemetics	Dexamethasone (Decadron?)	USE CAUTION due to the decreased survival rate/USE CAUTION due to the decreased survival rate	ABCB1	rs1045642 GG genotype/rs2032582 CC genotype	C34, C90	Multiple Myeloma	PGKB	2
Oncology	SLOW/SLOW	Antiemetics	Dronabinol (Marinol?)	USE CAUTION due to increased adverse reactions caused by reduced drug clearance/USE CAUTION due to increased adverse reactions caused by reduced drug clearance 	CYP2C9	Poor Metabolizer/Intermediate Metabolizer	C16, C18, C19, C20, C21, C25, C34, C43, C44, C50, C53, C61, C64, C67, C76	all types of cancer	FDA	1
Oncology	SLOW	Antiemetics (Selective 5-HT3 Receptor Antagonist)	Dolasetron (Anzemet?), Granisetron (Sancuso?)	USE CAUTION due to reduced response	CYP2D6	Ultrarapid Metabolizer	C16, C18, C19, C20, C21, C25, C34, C43, C44, C50, C53, C61, C64, C67, C76	all types of cancer	PGKB	2, 2
Oncology	SLOW/SLOW	Antiemetics (Selective 5-HT3 Receptor Antagonist)	Dolasetron (Anzemet?), Granisetron (Sancuso?)	USE CAUTION due to increased risk for QTc interval prolongation/USE CAUTION due to increased risk for QTc interval prolongation 	NOS1AP	rs10494366 GT genotype/rs10494366 TT genotype	C16, C18, C19, C20, C21, C25, C34, C43, C44, C50, C53, C61, C64, C67, C76	all types of cancer	PGKB	2, 2
Oncology	SLOW/SLOW/SLOW/SLOW/SLOW/SLOW	Antiemetics (Selective 5-HT3 Receptor Antagonist)	Ondansetron (Zofran?)	USE CAUTION due to increased likelihood of nausea and vomiting/USE CAUTION due to increased likelihood of nausea and vomiting/USE CAUTION due to increased likelihood of nausea and vomiting/USE CAUTION due to increased likelihood of nausea and vomiting/USE CAUTION due to increased likelihood of nausea and vomiting/USE CAUTION due to increased likelihood of nausea and vomiting	ABCB1	rs1045642 AG genotype/rs1045642 GG genotype/rs2032582 AC genotype/rs2032582 AT genotype/rs2032582 CC genotype/rs2032582 TT genotype	C16, C18, C19, C20, C21, C25, C34, C43, C44, C50, C53, C61, C64, C67, C76	all types of cancer	PGKB	2
Oncology	STOP	Antiemetics (Selective 5-HT3 Receptor Antagonist)	Ondansetron (Zofran?)	CONSIDER ALTERNATIVES which are not predominantly metabolized by CYP2D6	CYP2D6	Ultrarapid Metabolizer	C16, C18, C19, C20, C21, C25, C34, C43, C44, C50, C53, C61, C64, C67, C76	all types of cancer	CPIC	2
Oncology	GO	Antiemetics (Selective 5-HT3 Receptor Antagonist)	Palonosetron (Aloxi?)	NORMAL DOSE	CYP2D6	Poor Metabolizer	C16, C18, C19, C20, C21, C25, C34, C43, C44, C50, C53, C61, C64, C67, C76	all types of cancer	FDA	1
Oncology	STOP DOWN/DOWN	Antimetabolites (Purine Analog)	Mercaptopurine (Purinethol?), Thioguanine (Tabloid?)	CONSIDER ALTERNATIVES nonthiopurine immunosuppressant therapy for nonmalignant conditions or DECREASE DOSE by 90% of full dose and reduce frequency to thrice weekly then adjust doses of MP based on degree of myelosuppression /DECREASE DOSE by 30-70% of full dose then adjust doses of MP based on degree of myelosuppression 	TPMT	Poor Metabolizer/Intermediate Metabolizer	C81, C82, C83, C84, C90, C91, C92, C93, C94	leukemia, lymphoma	FDA, EMA, CPIC, DPWG	1, 1
Oncology	STOP/DOWN	Antimetabolites (Pyrimidine Analog) 	Capecitabine (Xeloda?), Fluorouracil (Carac?), Pyrimidinedione (Tegafur-Uracil?)	CONSIDER ALTERNATIVES/DECREASE DOSE by 50% at start followed by titration of dose based on toxicity or pharmacokinetic test	DPYD	Poor Metabolizer/Intermediate Metabolizer	C18, C20, C43, C44, C50, C61, C67, C76	breast and colon cancer, keratoses and skin cancer, breast colon gallbladder gastric head liver lung neck pancreatic prostate cancer	FDA, EMA, CPIC, DPWG	1, 1, 2
Oncology	SLOW	Antimetabolites (Pyrimidine Analog) 	Cytarabine (Depocyt?)	USE CAUTION due to decreased survival time and an increased risk of death 	CDA	rs532545 T Allele	C81, C82, C83, C84, C90, C91, C92, C93, C94	leukemia, lymphoma	PGKB	2
Oncology	SLOW/SLOW	Antimetabolites (Pyrimidine Analog) 	Fluorouracil (Carac?)	USE CAUTION due to increased risk of diarrhea/USE CAUTION due to increased risk of diarrhea	ABCB1	rs1045642 AA genotype/rs1045642 AG genotype	C18, C19, C20, C21	colorectal cancer	PGKB	2
Oncology	SLOW	Antimetabolites (Pyrimidine Analog) 	Fluorouracil (Carac?)	USE CAUTION due to an increased risk for nephrotoxicity, decreased survival and a poorer response 	ERCC1	rs11615 AA genotype	C16, C18, C19, C20, C21, C25, C43, C44, C50, C53, C61, C64, C67, C76	all types of cancer	PGKB	2
Oncology	SLOW	Antimetabolites (Pyrimidine Analog) 	Fluorouracil (Carac?)	USE CAUTION due to a highly increased risk of toxicity and poorer treatment outcome 	GSTP1	rs1695 AA genotype	C18, C19, C20, C21	colorectal cancer	PGKB	2
Oncology	SLOW/SLOW	Antimetabolites (Pyrimidine Analog) 	Fluorouracil (Carac?)	USE CAUTION due to poorer response and increased risk of toxicity/USE CAUTION due to poorer response and increased risk of toxicity	MTHFR	C677T Heterozygous Mutation/C677T Homozygous Mutation	C34, C50, C56, C81, C82, C83, C84, C85, C95	lung cancer, breast cancer, ovarian cancer, lymphoma, leukemia	PGKB	2
Oncology	SLOW	Antimetabolites (Pyrimidine Analog) 	Fluorouracil (Carac?)	USE CAUTION due to worse outcome including overall survival and progression-free survival	NQO1	rs1800566 AA genotype	C16, C34, C50	stomach cancer, lung cancer, breast cancer	PGKB	2
Oncology	SLOW/SLOW	Antimetabolites (Pyrimidine Analog) 	Fluorouracil (Carac?)	USE CAUTION due to decreased survival and response/USE CAUTION due to increased risk of severe neutropenia	XRCC1	rs25487 T Allele Carrier/rs25487 C Allele Carrier	C16, C18, C19, C20, C21, C25, C43, C44, C50, C53, C61, C64, C67, C76	all types of cancer	PGKB	2
Oncology	SLOW	BCR-ABL Tyrosine Kinase Inhibitors	Nilotinib (Tasigna?), Pazopanib (Votrient?)	USE CAUTION due to increased risk of hyperbilirubinemia	UGT1A1	Homozygous *28 Allele Carrier	C61, C64, C67	lung pancreatic cancer, leukemia, kidney, soft tissue	EMA	1, 1
Oncology	SLOW	BRAF Kinase Inhibitors	Dabrafenib (Tafinlar?)	USE CAUTION by closely observing patients with G6PD deficiency for signs of hemolytic anemia	G6PD	G6PD Deficiency	C43, C44	skin cancer	FDA	1
Oncology	SLOW	Chemotherapy Modulating Agents	Leucovorin (Wellcovorin?)	USE CAUTION due to an increased risk for nephrotoxicity, decreased survival and a poorer response 	ERCC1	rs11615 AA genotype	C16, C18, C19, C20, C21, C25, C43, C44, C50, C53, C61, C64, C67, C76	all types of cancer	PGKB	2
Oncology	SLOW	Chemotherapy Modulating Agents	Leucovorin (Wellcovorin?)	USE CAUTION due to a highly increased risk of toxicity and poorer treatment outcome 	GSTP1	rs1695 AA genotype	C18, C19, C20, C21	colorectal cancer	PGKB	3
Oncology	SLOW/SLOW	Chemotherapy Modulating Agents	Leucovorin (Wellcovorin?)	USE CAUTION due to poorer response and increased risk of toxicity/USE CAUTION due to poorer response and increased risk of toxicity	MTHFR	C677T Heterozygous Mutation/C677T Homozygous Mutation	C34, C50, C56, C81, C82, C83, C84, C85, C95	lung cancer, breast cancer, ovarian cancer, lymphoma, leukemia	PGKB	2
Oncology	SLOW/SLOW	Chemotherapy Modulating Agents	Leucovorin (Wellcovorin?)	USE CAUTION due to decreased survival and response/USE CAUTION due to increased risk of severe neutropenia	XRCC1	rs25487 T Allele Carrier/rs25487 C Allele Carrier	C16, C18, C19, C20, C21, C25, C43, C44, C50, C53, C61, C64, C67, C76	all types of cancer	PGKB	3
Oncology	SLOW	EGFR Tyrosine Kinase Inhibitors	Erlotinib (Tarceva?)	USE CAUTION due to increased risk of hyperbilirubinemia	UGT1A1	Homozygous *28 Allele Carrier	C61, C64, C67	lung pancreatic cancer, leukemia, kidney, soft tissue	EMA	2
Oncology	SLOW	EGFR Tyrosine Kinase Inhibitors	Gefitinib (Iressa?)	USE CAUTION due to possible adverse reactions 	CYP3A4	Poor Metabolizer	C34	lung cancer	EMA	2
Oncology	DOWN	EGFR Tyrosine Kinase Inhibitors	Ruxolitinib (Jakavi?)	DECREASE DOSE by 50% of the usual dose	CYP3A4	Poor Metabolizer	D48	bone marrow cancer	EMA	2
Oncology	SLOW/SLOW	Folate Antimetabolites	Methotrexate (Trexall?)	USE CAUTION due to increased risk of toxicity caused by increased drug concentration/USE CAUTION due to increased risk of toxicity caused by increased drug concentration	ABCB1	rs1045642 AA genotype/rs1045642 AG genotype	C81, C82, C83, C84, C90, C91, C92, C93, C94	leukemia, lymphoma	PGKB	2
Oncology	SLOW/SLOW	Folate Antimetabolites	Methotrexate (Trexall?)	USE CAUTION due to poorer response and increased risk of toxicity/USE CAUTION due to poorer response and increased risk of toxicity	MTHFR	C677T Heterozygous Mutation/C677T Homozygous Mutation	C34, C50, C56, C81, C82, C83, C84, C85, C95	lung cancer, breast cancer, ovarian cancer, lymphoma, leukemia	PGKB	2
Oncology	SLOW/SLOW	Folate Antimetabolites	Pemetrexed (Alimta?)	USE CAUTION due to poorer response and increased risk of toxicity/USE CAUTION due to poorer response and increased risk of toxicity	MTHFR	C677T Heterozygous Mutation/C677T Homozygous Mutation	C34, C50, C56, C81, C82, C83, C84, C85, C95	lung cancer, breast cancer, ovarian cancer, lymphoma, leukemia	PGKB	2
Oncology	DOWN	Histone Deacetylase (HDAC) Inhibitors	Belinostat (Beleodaq?)	DECREASE DOSE to 750 mg per square meter of body surface	UGT1A1	Homozygous *28 Allele Carrier	C16, C18, C19, C20, C21, C25, C43, C44, C50, C53, C61, C64, C67, C76	all types of cancer	FDA	1
Oncology	SLOW	Immunomodulators	Thalidomide (Thalomid?)	USE CAUTION due to decreased overall survival 	ERCC1	rs735482 AA genotype			PGKB	2
Oncology	SLOW	Platinum Analog	Carboplatin (Paraplatin?), Cisplatin (Platinol?), Oxaliplatin (Eloxatin?)	USE CAUTION due to an increased risk for nephrotoxicity, decreased survival and a poorer response 	ERCC1	rs11615 AA genotype	C16, C18, C19, C20, C21, C25, C43, C44, C50, C53, C61, C64, C67, C76	all types of cancer	PGKB	2, 2, 2
Oncology	SLOW	Platinum Analog	Carboplatin (Paraplatin?), Cisplatin (Platinol?), Oxaliplatin (Eloxatin?)	USE CAUTION due to a highly increased risk of toxicity and poorer treatment outcome 	GSTP1	rs1695 AA genotype	C18, C19, C20, C21	colorectal cancer	PGKB	2, 2, 2
Oncology	SLOW/SLOW	Platinum Analog	Carboplatin (Paraplatin?), Cisplatin (Platinol?), Oxaliplatin (Eloxatin?)	USE CAUTION due to decreased survival and response/USE CAUTION due to increased risk of severe neutropenia	XRCC1	rs25487 T Allele Carrier/rs25487 C Allele Carrier	C16, C18, C19, C20, C21, C25, C43, C44, C50, C53, C61, C64, C67, C76	all types of cancer	PGKB	2, 2, 2
Oncology	SLOW/SLOW	Platinum Analog	Carboplatin (Paraplatin?), Oxaliplatin (Eloxatin?)	USE CAUTION due to poorer response and increased risk of toxicity/USE CAUTION due to poorer response and increased risk of toxicity	MTHFR	C677T Heterozygous Mutation/C677T Homozygous Mutation	C34, C50, C56, C81, C82, C83, C84, C85, C95	lung cancer, breast cancer, ovarian cancer, lymphoma, leukemia	PGKB	2, 2
Oncology	SLOW	Platinum Analog	Cisplatin (Platinol?)	USE CAUTION due to increased risk for nephrotoxicity or mucositis	ERCC1	rs3212986 C Allele Carrier	C50, C56	breast cancer, ovarian cancer	PGKB	2
Oncology	SLOW	Platinum Analog	Cisplatin (Platinol?), Oxaliplatin (Eloxatin?)	USE CAUTION due to worse outcome including overall survival and progression-free survival	NQO1	rs1800566 AA genotype	C16, C34, C50	stomach cancer, lung cancer, breast cancer	PGKB	2, 2
Oncology	STOP/STOP	Selective Estrogen Receptor Modulators (SERMs)	Tamoxifen (Soltamox?)	CONSIDER ALTERNATIVES like aromatase inhibitor for postmenopausal women due to increased risk for relapse of breast cancer/CONSIDER ALTERNATIVES like aromatase inhibitor for postmenopausal women due to increased risk for relapse of breast cancer	CYP2D6	Poor Metabolizer/Intermediate Metabolizer	C50	breast cancer, precocious puberty, retroperitoneal fibrosis, pancreatic tumor	FDA, HCSC, DPWG	2
Oncology	SLOW	Selective Estrogen Receptor Modulators (SERMs)	Tamoxifen (Soltamox?)	USE CAUTION due to increase in the incidence of thromboembolic effects	F2	F2 G20210A Mutation	C50	breast cancer	FDA	1
Oncology	DOWN	Taxane Derivatives	Cabazitaxel (Jevtana?)	DECREASE DOSE by 25% of the usual dose	CYP3A4	Poor Metabolizer	C61	prostate cancer	EMA	2
Oncology	SLOW	Taxane Derivatives	Docetaxel (Taxotere?)	USE CAUTION due to increased risk for nephrotoxicity or mucositis 	ERCC1	rs3212986 C Allele Carrier	C50, C56	breast cancer, ovarian cancer	PGKB	2
Oncology	SLOW	Taxane Derivatives	Paclitaxel (Abraxane?)	USE CAUTION due to decreased response	ABCB1	rs2032582 CC genotype	C50, C56	breast cancer, ovarian cancer	PGKB	2
Oncology	SLOW	Taxane Derivatives	Paclitaxel (Abraxane?)	USE CAUTION due to increased risk for nephrotoxicity or mucositis 	ERCC1	rs3212986 C Allele Carrier	C50, C56	breast cancer, ovarian cancer	PGKB	2
Oncology	DOWN	Topoisomerase I Inhibitors	Irinotecan (Camptosar?)	DECREASE DOSE at start by at least one level due to increased risk for neutropenia	UGT1A1	Homozygous *28 Allele Carrier	C18, C20	colon, leukemia, lung, lymphoma	FDA, DPWG	1
Oncology	SLOW/SLOW	Topoisomerase II Inhibitors	Idarubicin (Idamycin?)	USE CAUTION due to increased likelihood of toxic liver disease/USE CAUTION due to increased likelihood of toxic liver disease 	SLCO1B1	Low Activity/Intermediate Activity	C81, C82, C83, C84, C90, C91, C92, C93, C94	leukemia, lymphoma	PGKB	2
Oncology	STOP	Urate-Oxidases (Recombinant)	Rasburicase (Elitek?)	CONSIDER ALTERNATIVES include allopurinol 	G6PD	G6PD Deficiency	C81, C82, C83, C84, C90, C91, C92, C93, C94	leukemia, lymphoma	FDA, EMA, CPIC	1
Oncology	SLOW/SLOW	VEGF Tyrosine Kinase Inhibitors	Sorafenib (NexAvar?)	USE CAUTION due to increased risk of hyperbilirubinemia and treatment interruption/USE CAUTION due to increased risk of hyperbilirubinemia and treatment interruption	UGT1A1	Heterozygous *28 Allele Carrier/Homozygous *28 Allele Carrier	C64, C22, C73	kidney, liver, and thyroid cancer	PGKB	2
Oncology	STOP DOWN	VEGF Tyrosine Kinase Inhibitors	Sunitinib (Sutent?)	CONSIDER ALTERNATIVES or DECREASE DOSE	CYP3A4	Poor Metabolizer	C25, C64	late-stage kidney cancer, gastrointestinal stromal tumor, pancreatic neuroendocrine tumor 	EMA	2
Oncology	SLOW/SLOW	Vinca Alkaloids	Vincristine (Marqibo?)	USE CAUTION due to the decreased survival rate/USE CAUTION due to the decreased survival rate	ABCB1	rs1045642 GG genotype/rs2032582 CC genotype	C90	Multiple Myeloma	PGKB	2
Osteoporosis	SLOW/SLOW	Selective Estrogen Receptor Modulators (SERMs)	Raloxifene (Evista?)	USE CAUTION due to decreased hip bone mineral density/USE CAUTION due to decreased hip bone mineral density	UGT1A1	Non *28 Allele Carrier/Heterozygous *28 Allele Carrier	M13, M15, M16, M17, M18, M19	osteoporosis	PGKB	2
Pain Management	SLOW/SLOW	Alpha-2 Adrenergic Agonists	Tizanidine (Zanaflex?)	USE CAUTION due to increased risk of adverse symptoms/USE CAUTION due to increased risk for loss of efficacy	CYP1A2	Poor Metabolizer/Ultrarapid Metabolizer	R25, R29, M62, M72, M79	pain	Literature	3
Pain Management	DOWN/SLOW	Nonsteroidal Antiinflammatory Drugs (NSAIDs)	Celecoxib (Celebrex?), Diclofenac (Voltaren?), Meloxicam (Mobic?)	DECREASE DOSE by 50%/USE CAUTION due to increased exposure to the drug	CYP2C9	Poor Metabolizer/Intermediate Metabolizer	G56, M06, M12, M15, M16, M17, M19, M25, M45, M46, M65, M70, M71, M75, M77, M81, M85, M94, N20	Pain, Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Menstrual cramps	FDA, EMA	1, 2, 2
Pain Management	SLOW/SLOW	Nonsteroidal Antiinflammatory Drugs (NSAIDs)	Ibuprofen (Advil?), Naproxen (Aleve?)	USE CAUTION due to the risk of increased exposure to the drug leading to adverse events/USE CAUTION due to the risk of increased exposure to the drug leading to adverse events	CYP2C9	Poor Metabolizer/Intermediate Metabolizer	G56, M06, M12, M15, M16, M17, M19, M25, M45, M46, M65, M70, M71, M75, M77, M81, M85, M94, N20	Pain, Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Menstrual cramps	Literature	3, 3
Pain Management	DOWN	Nonsteroidal Antiinflammatory Drugs (NSAIDs)	Piroxicam (Feldene?)	DECREASE DOSE due to reduced drug metabolic clearance	CYP2C9	Poor Metabolizer	M13, M15, M16, M17, M18, M19	osteoporosis	FDA	1
Pain Management	UP	Opioids	Alfentanil (Alfenta?), Fentanyl (Duragesic?), Hydromorphone (Dilaudid?), Morphine (MS Contin?)	INCREASE DOSE due to decreased efficacy	OPRM1	rs1799971 G Allele Carrier	F11, G62, G64, G89, M12, M47, M50, M51, M53, M54, M96, R52	pain	PGKB Level 2B	2, 2, 3, 2
Pain Management	DOWN SLOW/DOWN SLOW	Opioids	Buprenorphine (Subutex?), Fentanyl (Duragesic?), Hydrocodone/Acetaminophen (Vicodin?), Methadone (Methadose?), Oxycodone (Oxycontin?), Sufentanil (Sufenta?)	DECREASE DOSE or USE CAUTION due to the risk of increased exposure to the drug leading to adverse events/DECREASE DOSE or USE CAUTION due to the risk of increased exposure to the drug leading to adverse events	CYP3A4	Poor Metabolizer/Intermediate Metabolizer	F11, G62, G64, G89, M12, M47, M50, M51, M53, M54, M96, R52	pain	Quest Diagnostics, Literature	3, 3, 3, 3, 3, 3
Pain Management	STOP/STOP/STOP	Opioids	Codeine (Codeine?), Codeine/Acetaminophen (Tylenol #3 & #4?), Hydrocodone/Acetaminophen (Vicodin?), Oxycodone (Oxycontin?)	CONSIDER ALTERNATIVES due to lack of efficacy/CONSIDER ALTERNATIVES if no response/CONSIDER ALTERNATIVES due to potential toxicity	CYP2D6	Poor Metabolizer/Intermediate Metabolizer/Ultrarapid Metabolizer	F11, G62, G64, G89, M12, M47, M50, M51, M53, M54, M96, R52	pain	FDA, HCSC, CPIC, DPWG, CPNDS	2, 2, 2, 2
Pain Management	SLOW	Opioids	Hydrocodone/Acetaminophen (Vicodin?)	USE CAUTION due to increased risk for experiencing side effects	OPRM1	rs1799971 G Allele Carrier	F11, G62, G64, G89, M12, M47, M50, M51, M53, M54, M96, R52	pain	PGKB Level 3	2
Pain Management	DOWN/DOWN	Opioids	Methadone (Methadose?)	DECREASE DOSE/DECREASE DOSE	CYP2B6	G516T Homozygous/A785G Homozygous	F11, G62, G64, G89, M12, M47, M50, M51, M53, M54, M96, R52	pain, drug dependence	PGKB	2
Pain Management	DOWN	Opioids	Methadone (Methadose?)	DECREASE DOSE	DRD2	rs1799978 C allele Carrier	F11, G62, G64, G89, M12, M47, M50, M51, M53, M54, M96, R52	pain, drug dependence	PGKB	2
Pain Management	SLOW	Opioids	Methadone (Methadose?)	USE CAUTION due to increased severity of sleep disorders 	OPRM1	rs1799971 A Allele Carrier	F11, G62, G64, G89, M12, M47, M50, M51, M53, M54, M96, R52	pain, drug dependence	PGKB	2
Pain Management	STOP/STOP UP/STOP DOWN	Opioids	Tramadol Hydrochloride/Acetaminophen (Ultracet?), Tramadol (Ultram?)	CONSIDER ALTERNATIVES (not oxycodone, codeine)/CONSIDER ALTERNATIVES (not oxycodone, codeine) or INCREASE DOSE/CONSIDER ALTERNATIVES (acetaminophen, NSAID, morphine-not oxycodone, codeine) or DECREASE DOSE by 30%	CYP2D6	Poor Metabolizer/Intermediate Metabolizer/Ultrarapid Metabolizer	F11, G62, G64, G89, M12, M47, M50, M51, M53, M54, M96, R52	pain	FDA, HCSC, DPWG	1, 1
Pain Management	SLOW	Skeletal Muscle Relaxants	Carisoprodol (Soma?)	USE CAUTION due to increased exposure to the drug	CYP2C19	Poor Metabolizer	R25, R29, M62, M72, M79	Pain, Muscle Spasms, Cramp, Spasticity, Inflammation of the skeletal muscle, Muscle Rigidity	FDA	2
Pain Management	DOWN SLOW/UP SLOW	Skeletal Muscle Relaxants	Cyclobenzaprine (Flexeril?)	DECREASE DOSE or USE CAUTION due to the risk of increased exposure to the drug leading to adverse events/INCREASE DOSE or USE CAUTION due to the risk of decreased exposure to the drug leading to lower effectiveness	CYP1A2	Poor Metabolizer/Ultrarapid Metabolizer	R25, R29, M62, M72, M79	Pain, Muscle Spasms, Cramp, Spasticity, Inflammation of the skeletal muscle, Muscle Rigidity	Literature	3
Psychiatry	GO/GO	Aldehyde Dehydrogenase Inhibitors	Disulfiram (Antabuse?)	NORMAL DOSE may have an increased likelihood of response/NORMAL DOSE may have an increased likelihood of response	ANKK1	A1 Homozygous/A1 Heterozygous	F10, F14	chronic alcoholism, Cocaine-Related Disorders	PGKB	2
Psychiatry	SLOW/SLOW/SLOW	Alpha-2 Antagonists	Mirtazapine (Remeron?)	USE CAUTION due to decreased drug response/USE CAUTION due to possible increased ADRs/USE CAUTION due to possible increased ADRs	CYP2D6	Ultrarapid Metabolizer/Poor Metabolizer/Intermediate Metabolizer	F20, F23, F25, F31, F32, F33, F34, F40, F41, F42, F43, F63	depression, obsessive-compulsive disorder (OCD), panic disorder, generalized anxiety disorder (GAD), social anxiety disorder	PGKB	2
Psychiatry	SLOW	Anti-Anxiety Agents	Buspirone (Buspar?)	USE CAUTION due to reduced response 	HTR1A	rs1800044 A Allele Carrier	F20, F25, F41	Anxiety, Agoraphobia, Panic disorder, Depressive Disorder	Literature	3
Psychiatry	SLOW/SLOW	Antimanic Agents	Lithium (Lithobid?)	USE CAUTION due to possible less drug response/USE CAUTION due to possible less drug response	ABCB1	rs2032582 AA genotype/rs2032582 AC genotype	F20, F25, F41, F63	Anxiety, Agoraphobia, Panic disorder, Depressive Disorder	PGKB	2
Psychiatry	DOWN	Antipsychotics	Aripiprazole (Abilify?)	DECREASE DOSE by 50% of the usual dose	CYP3A4	Poor Metabolizer	F20, F23, F25, F31, F32, F33, F34, F84	bipolar, schizophrenia, autism	EMA	2
Psychiatry	DOWN	Antipsychotics	Aripiprazole (Abilify?), Brexpiprazole (Rexulti?), Iloperidone (Fanapt?), Pimozide (Orap?)	DECREASE DOSE by 50% of the usual dose and then adjusted to achieve a favorable clinical response	CYP2D6	Poor Metabolizer	F20, F23, F25, F31, F32, F33, F34, F84	bipolar, schizophrenia, autism	FDA, EMA, DPWG	1, 1, 1, 1
Psychiatry	SLOW/SLOW/SLOW	Antipsychotics	Chlorpromazine, Fluphenazine	USE CAUTION due to possible increased QT interval/USE CAUTION due to possible increased QT interval/USE CAUTION due to possible increased QT interval	CYP1A2	Poor Metabolizer/Intermediate Metabolizer/Normal Metabolizer	F20, F22, F23, F25, F31, F32, F33, F34	Schizophrenia, Bipolar disorder, Psychosis	PGKB	2, 2
Psychiatry	SLOW	Antipsychotics	Clozapine (Clozaril?)	USE CAUTION due to an increased risk for seizures	CYP1A2	High Inducibility Metabolizer	F20, F22, F23, F25, F31, F32, F33, F34, F84	Schizophrenia, Bipolar disorder, Dementia, Autism, Tourette syndrome	PGKB	2
Psychiatry	DOWN SLOW	Antipsychotics	Clozapine (Clozaril?)	DECREASE DOSE or USE CAUTION when administering concomitantly with drugs that are inducers or inhibitors of CYP2D6	CYP2D6	Poor Metabolizer	F20, F22, F23, F25, F31, F32, F33, F34, F84	Schizophrenia, Bipolar disorder, Dementia, Autism, Tourette syndrome	FDA	1
Psychiatry	SLOW/SLOW	Antipsychotics	Clozapine (Clozaril?)	USE CAUTION due to increased risk of side effects including hyperprolactinemia and weight gain/USE CAUTION due to increased risk of side effects including hyperprolactinemia and weight gain	ANKK1	A1 Homozygous/A1 Heterozygous	F20, F22, F23, F25, F31, F32, F33, F34, F84	Schizophrenia, Bipolar disorder, Dementia, Autism, Tourette syndrome	PGKB	2
Psychiatry	SLOW/SLOW	Antipsychotics	Olanzapine (Zyprexa?)	USE CAUTION due to increased risk of side effects including hyperprolactinemia and weight gain/USE CAUTION due to increased risk of side effects including hyperprolactinemia and weight gain	ANKK1	A1 Homozygous/A1 Heterozygous	F20, F22, F23, F25, F31, F32, F33, F34, F84	Schizophrenia, Bipolar disorder, Dementia, Autism, Tourette syndrome	PGKB	2
Psychiatry	SLOW/SLOW	Antipsychotics	Risperidone (Risperdal?)	USE CAUTION due to increased risk of side effects including hyperprolactinemia and weight gain/USE CAUTION due to increased risk of side effects including hyperprolactinemia and weight gain	ANKK1	A1 Homozygous/A1 Heterozygous	F20, F22, F23, F25, F31, F32, F33, F34, F84	Schizophrenia, Bipolar disorder, Dementia, Autism, Tourette syndrome	PGKB	2
Psychiatry	SLOW	Antipsychotics	Clozapine (Clozaril?)	USE CAUTION due to increased risk of developing metabolic syndrome 	HTR2C	rs1414334 C Allele Carrier	F20, F22, F23, F25, F31, F32, F33, F34, F84	Schizophrenia, Bipolar disorder, Dementia, Autism, Tourette syndrome	PGKB	2
Psychiatry	SLOW	Antipsychotics	Olanzapine (Zyprexa?)	USE CAUTION due to increased risk of developing metabolic syndrome 	HTR2C	rs1414334 C Allele Carrier	F20, F22, F23, F25, F31, F32, F33, F34, F84	Schizophrenia, Bipolar disorder, Dementia, Autism, Tourette syndrome	PGKB	2
Psychiatry	SLOW	Antipsychotics	Risperidone (Risperdal?)	USE CAUTION due to increased risk of developing metabolic syndrome 	HTR2C	rs1414334 C Allele Carrier	F20, F22, F23, F25, F31, F32, F33, F34, F84	Schizophrenia, Bipolar disorder, Dementia, Autism, Tourette syndrome	PGKB	2
Psychiatry	STOP DOWN/STOP 	Antipsychotics	Haloperidol (Haldol?)	CONSIDER ALTERNATIVES (e.g., pimozide, flupenthixol, fluphenazine, quetiapine, olanzapine, clozapine) or DECREASE DOSE by 50%/CONSIDER ALTERNATIVES (e.g., pimozide, flupenthixol, fluphenazine, quetiapine, olanzapine, clozapine)	CYP2D6	Poor Metabolizer/Ultrarapid Metabolizer	F20, F22, F25, F31, F32, F33, F34	Schizophrenia, Bipolar, Psychosis, Tourette syndrome, Vomiting, Alzheimer's disease, Child Behavior Disorders, Withdrawal syndrome	DPWG	2
Psychiatry	DOWN/UP	Antipsychotics	Olanzapine (Zyprexa?)	DECREASE DOSE due to reduced rate of drug clearance/INCREASE DOSE due to decreased response	CYP1A2	Poor Metabolizer/High Inducibility Metabolizer	F20, F22, F23, F25, F31, F32, F33, F34	Schizophrenia, Bipolar disorder, Psychosis	EMA	2
Psychiatry	SLOW	Antipsychotics	Olanzapine (Zyprexa?), Quetiapine (Seroquel?)	USE CAUTION due to increased risk of side effects 	SLC6A4	HTTLPR Long Form	F20, F22, F23, F25, F31, F32, F33, F34	Schizophrenia, Bipolar disorder, Psychosis	PGKB	2, 2
Psychiatry	SLOW	Antipsychotics	Risperidone (Risperdal?)	USE CAUTION due to increased risk of side effects 	SLC6A4	HTTLPR Long Form	F20, F22, F23, F25, F31, F32, F33, F34	Schizophrenia, Bipolar disorder, Psychosis	PGKB	2
Psychiatry	DOWN	Antipsychotics	Perphenazine	DECREASE DOSE due to significantly greater side effects	CYP2D6	Poor Metabolizer	F20, F25, F31, F32, F33, F34, F84	Schizophrenia, Bipolar disorder, Dementia, Autism, Tourette syndrome	FDA, PMDA	1
Psychiatry	SLOW/SLOW	Antipsychotics	Quetiapine (Seroquel?)	USE CAUTION due to increased likelihood of higher percentage of weight gain/USE CAUTION due to increased likelihood of higher percentage of weight gain	FAAH	rs324420 AA genotype/rs324420 CA genotype	F20, F22, F23, F25, F31, F32, F33, F34	Schizophrenia, Bipolar disorder, Psychosis	PGKB	2
Psychiatry	STOP/STOP/STOP	Antipsychotics	Risperidone (Risperdal?)	CONSIDER ALTERNATIVES (e.g., quetiapine, olanzapine, clozapine)/CONSIDER ALTERNATIVES (e.g., quetiapine, olanzapine, clozapine)/CONSIDER ALTERNATIVES (e.g., quetiapine, olanzapine, clozapine)	CYP2D6	Poor Metabolizer/Intermediate Metabolizer/Ultrarapid Metabolizer	F20, F22, F23, F25, F31, F32, F33, F34, F84	Schizophrenia, Bipolar disorder, Dementia, Autism, Tourette syndrome	FDA, DPWG	1
Psychiatry	SLOW	Antipsychotics	Risperidone (Risperdal?)	USE CAUTION due to reduced symptoms improvement and increased risk of Hyperprolactinemia 	DRD2	rs1799978 C allele Carrier	F20, F22, F23, F25, F31, F32, F33, F34, F84	Schizophrenia, Bipolar disorder, Dementia, Autism, Tourette syndrome	PGKB	2
Psychiatry	STOP/STOP	Antipsychotics	Thioridazine (Mellaril?)	CONSIDER ALTERNATIVES/CONSIDER ALTERNATIVES	CYP2D6	Poor Metabolizer/Intermediate Metabolizer	F20, F22, F25, F31, F32, F33, F34	Schizophrenia, Bipolar disorder, Psychosis	FDA	1
Psychiatry	SLOW	Benzodiazepines	Alprazolam (Xanax?)	USE CAUTION due to the risk of increased exposure to the drug leading to adverse events	CYP3A4	Poor Metabolizer	F20, F25, F41, F51, G47	Anxiety, Agoraphobia, Panic disorder, Depressive Disorder	Literature	3
Psychiatry	SLOW/SLOW/SLOW/SLOW	Benzodiazepines	Diazepam (Valium?)	USE CAUTION due to possible increased ADRs/USE CAUTION due to possible increased ADRs/USE CAUTION due to decreased drug response/USE CAUTION due to decreased drug response	CYP2C19	Poor Metabolizer/Intermediate Metabolizer/Rapid Metabolizer/Ultrarapid Metabolizer	F20, F25, F41, F51, G47	Anxiety, Agoraphobia, Panic disorder, Depressive Disorder	PGKB	1
Psychiatry	SLOW	Benzodiazepines	Lorazepam (Ativan?), Oxazepam (Serax?)	USE CAUTION due to increased risk of side effects caused by decreased clearance of drug	UGT2B15	rs1902023 AA genotype	F20, F25, F41, F51, G47	Anxiety, Agoraphobia, Panic disorder, Depressive Disorder	PGKB	2, 2
Psychiatry	SLOW	Benzodiazepines	Midazolam (Versed?)	USE CAUTION due to increased risk of side effects caused by decreased clearance of drug	CYP3A5	Non Expresser	F20, F25, F41, F51, G47	Anxiety, Agoraphobia, Panic disorder, Depressive Disorder	PGKB	2
Psychiatry	SLOW	CNS Stimulants (ADHD)	Amphetamine (Adderall?)	USE CAUTION due to reduced response 	OPRM1	rs510769 TT genotype	F84, F90	ADHD, Autism 	PGKB	2
Psychiatry	SLOW	CNS Stimulants (ADHD)	Amphetamine (Adderall?), Dexmethylphenidate (Focalin?), Dextroamphetamine (Adderall?), Lisdexamfetamine (Vyvanse?), Methylphenidate (Ritalin?)	USE CAUTION due to reduced response 	COMT	MET Homozygous	F84, F90	ADHD, Autism 	PGKB	2, 2, 2, 3, 2
Psychiatry	SLOW	CNS Stimulants (ADHD)	Dextroamphetamine (Adderall?), Methylphenidate (Ritalin?)	USE CAUTION due to increased severity of social withdrawal or nausea 	DRD1	rs4532 CC genotype	F84, F90	ADHD, Autism 	PGKB	2, 2
Psychiatry	SLOW/SLOW	CNS Stimulants (ADHD)	Methamphetamine (Desoxyn?)	USE CAUTION due to increased risk for drug dependence/USE CAUTION due to increased risk for drug dependence 	FAAH	rs324420 CA genotype/rs324420 AA genotype	F84, F90	ADHD, Autism 	PGKB	2
Psychiatry	DOWN	CNS Stimulants (ADHD)	Methylphenidate (Ritalin?)	DECREASE DOSE	CES1	rs71647871 T Allele	F84, F90	ADHD, Autism 	PGKB	2
Psychiatry	SLOW/SLOW	Dopamine/Norepinephrine-Reuptake Inhibitors	Bupropion (Wellbutrin?)	USE CAUTION due to reduced response and increased risk of side effects/USE CAUTION due to reduced response and increased risk of side effects	CYP2B6	G516T Heterozygous/G516T Homozygous	F20, F23, F25, F31, F32, F33, F34, F40, F41, F42, F43, F63, F84,	depression, obsessive-compulsive disorder (OCD), panic disorder, generalized anxiety disorder (GAD), social anxiety disorder, autism	PGKB	2
Psychiatry	SLOW/SLOW	Dopamine/Norepinephrine-Reuptake Inhibitors	Bupropion (Wellbutrin?)	USE CAUTION due to reduced response and increased risk of side effects/USE CAUTION due to reduced response and increased risk of side effects	CYP2C19	Poor Metabolizer/Intermediate Metabolizer	F20, F23, F25, F31, F32, F33, F34, F40, F41, F42, F43, F63, F84,	depression, obsessive-compulsive disorder (OCD), panic disorder, generalized anxiety disorder (GAD), social anxiety disorder, autism	PGKB	2
Psychiatry	UP	Opioids Antagonists	Naloxone (Evzio?), Naltrexone (Revia?)	INCREASE DOSE due to decreased efficacy	OPRM1	rs1799971 G Allele Carrier	F10, F84	drug dependence, drug overdose, alcohol abuse, autism	PGKB	2, 2
Psychiatry	SLOW/SLOW	Other Stimulants	Cannabinoids	USE CAUTION due to increased risk of tetrahydrocannabinol (THC) dependence/USE CAUTION due to increased risk of tetrahydrocannabinol (THC) dependence	FAAH	rs324420 CC genotype/rs324420 CA genotype	F12	Cannabis use	PGKB	2
Psychiatry	SLOW	Other Stimulants	Cocaine	USE CAUTION due to increased risk of cocaine dependence 	CNR1	rs806368 TT genotype	F14	cocaine-related disorder	PGKB	2
Psychiatry	SLOW	Selective Serotonin Reuptake Inhibitors (SSRIs)	Citalopram (Celexa?)	USE CAUTION due to reduced response	GRIK4	rs1954787 T Allele Carrier	F20, F23, F25, F31, F32, F33, F34, F40, F41, F43	Major depression, Obsessive-compulsive disorder, Alcoholism, Dementia, Diabetic nerve damage, Tobacco abuse, Depressive Disorder	PGKB Level 3	2
Psychiatry	SLOW	Selective Serotonin Reuptake Inhibitors (SSRIs)	Citalopram (Celexa?)	USE CAUTION due to less improvement in symptoms	HTR2A	rs7997012 GG genotype	F20, F23, F25, F31, F32, F33, F34, F40, F41, F43	Major depression, Obsessive-compulsive disorder, Alcoholism, Dementia, Diabetic nerve damage, Tobacco abuse, Depressive Disorder	PGKB Level 2B	2
Psychiatry	STOP DOWN/STOP UP/STOP UP	Selective Serotonin Reuptake Inhibitors (SSRIs)	Citalopram (Celexa?), Escitalopram (Lexapro?)	CONSIDER ALTERNATIVES or DECREASE DOSE by 50% of the recommended starting dose (maximum daily dose of 20 mg) and titrate to response/CONSIDER ALTERNATIVES or INCREASE DOSE by 150% in response to efficacy and adverse drug event/CONSIDER ALTERNATIVES or INCREASE DOSE by 150% in response to efficacy and adverse drug event	CYP2C19	Poor Metabolizer/Rapid Metabolizer/Ultrarapid Metabolizer	F20, F23, F25, F31, F32, F33, F34, F40, F41, F43	Major depression, Obsessive-compulsive disorder, Alcoholism, Dementia, Diabetic nerve damage, Tobacco abuse, Depressive Disorder	FDA, HCSC, CPIC, DPWG	1, 1
Psychiatry	SLOW	Selective Serotonin Reuptake Inhibitors (SSRIs)	Citalopram (Celexa?), Escitalopram (Lexapro?)	USE CAUTION due to decreased response 	SLC6A4	HTTLPR Short Form	F20, F23, F25, F31, F32, F33, F34, F40, F41, F43	Major depression, Obsessive-compulsive disorder, Alcoholism, Dementia, Diabetic nerve damage, Tobacco abuse, Depressive Disorder	PGKB Level 2A	2, 2
Psychiatry	SLOW/SLOW	Selective Serotonin Reuptake Inhibitors (SSRIs)	Fluoxetine (Prozac?)	USE CAUTION due to elevated risk for drug overdose resulting in adverse events and drug interactions/USE CAUTION due to elevated risk for drug overdose resulting in adverse events and drug interaction	CYP2D6	Poor Metabolizer/Intermediate Metabolizer	F20, F23, F25, F31, F32, F33, F34, F40, F41, F42, F43, F50, F63, F84	depression, obsessive-compulsive disorder (OCD), panic disorder, generalized anxiety disorder (GAD), social anxiety disorder, autism, eating disorder	FDA, Medscape	1
Psychiatry	STOP DOWN	Selective Serotonin Reuptake Inhibitors (SSRIs)	Fluvoxamine (Luvox?)	CONSIDER ALTERNATIVES or DECREASE DOSE by 25-50% of recommended starting dose and titrate to response 	CYP2D6	Poor Metabolizer	F20, F23, F25, F31, F32, F33, F34, F40, F41, F42, F43, F63	depression, obsessive-compulsive disorder (OCD), panic disorder, generalized anxiety disorder (GAD), social anxiety disorder	CPIC	1
Psychiatry	SLOW	Selective Serotonin Reuptake Inhibitors (SSRIs)	Fluvoxamine (Luvox?), Paroxetine (Paxil?), Sertraline (Zoloft?)	USE CAUTION due to reduced response 	HTR1A	rs6295 CC genotype	F20, F23, F25, F31, F32, F33, F34, F40, F41, F42, F43, F50, F63	depression, obsessive-compulsive disorder (OCD), panic disorder, generalized anxiety disorder (GAD), social anxiety disorder, eating disorder	PGKB	2, 2, 2
Psychiatry	STOP DOWN/STOP	Selective Serotonin Reuptake Inhibitors (SSRIs)	Paroxetine (Paxil?)	CONSIDER ALTERNATIVES or DECREASE DOSE by 50% of recommended starting dose and titrate to response/CONSIDER ALTERNATIVES 	CYP2D6	Poor Metabolizer/Ultrarapid Metabolizer	F20, F23, F25, F31, F32, F33, F34, F40, F41, F42, F43	depression, obsessive-compulsive disorder (OCD), panic disorder, generalized anxiety disorder (GAD), social anxiety disorder	CPIC	1
Psychiatry	STOP DOWN/SLOW/STOP/STOP	Selective Serotonin Reuptake Inhibitors (SSRIs)	Sertraline (Zoloft?)	CONSIDER ALTERNATIVES or DECREASE DOSE by 50%/USE CAUTION with high alert to adverse drug events/CONSIDER ALTERNATIVES for non-responders/CONSIDER ALTERNATIVES for non-responders	CYP2C19	Poor Metabolizer/Intermediate Metabolizer/Rapid Metabolizer/Ultrarapid Metabolizer	F20, F23, F25, F31, F32, F33, F34, F40, F41, F42, F43, F50, F63	Major depression, Obsessive-compulsive disorder, Panic disorder, Posttraumatic stress disorder, Eating disorder, Depressive Disorder	FDA, CPIC, DPWG	2
Psychiatry	DOWN	Selective Serotonin Reuptake Inhibitors (SSRIs)	Vilazodone (Viibryd?)	DECREASE DOSE by 50%	CYP3A4	Poor Metabolizer	F20, F25, F31, F32, F33, F34, F40, F41, F43	depression, obsessive-compulsive disorder (OCD), panic disorder, generalized anxiety disorder (GAD), social anxiety disorder	Literature	3
Psychiatry	DOWN	Selective Serotonin Reuptake Inhibitors (SSRIs)	Vortioxetine (Trintellix?)	DECREASE DOSE to 10mg daily	CYP2D6	Poor Metabolizer	F20, F25, F31, F32, F33, F34, F40, F41, F43	Major depression, Anxiety disorder	FDA	1
Psychiatry	SLOW/STOP	Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)	Atomoxetine (Strattera?)	USE CAUTION be alert to ADEs and make necessary dose adjustments/CONSIDER ALTERNATIVES 	CYP2D6	Poor Metabolizer/Ultrarapid Metabolizer	F84, F90	Autism, ADHD	FDA, DPWG	1
Psychiatry	SLOW	Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)	Duloxetine (Cymbalta?)	USE CAUTION due to increased exposure to the drug	CYP1A2	Poor Metabolizer	F20, F23, F25, F31, F32, F33, F34, F40, F41, F43, F84, F90	Major depression, Pain, Obsessive-compulsive disorder, Attention deficit hyperactivity disorder, Autism, Chronic fatigue syndrome, Depressive Disorder, narcolepsy	FDA	3
Psychiatry	DOWN	Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)	Levomilnacipran (Fetzima?)	DECREASE DOSE to less than 80mg daily	CYP3A4	Poor Metabolizer	F20, F25, F31, F32, F33, F34, F40, F41, F43, F84, F90	Major depression, Pain, Obsessive-compulsive disorder, Attention deficit hyperactivity disorder, Autism, Chronic fatigue syndrome, Depressive Disorder, narcolepsy	Literature	3
Psychiatry	SLOW	Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)	Milnacipran (Savella?)	USE CAUTION due to reduced response 	ADRA2A	rs1800544 GG genotype	F20, F23, F25, F31, F32, F33, F34, F40, F41, F42, F43, F63, K58	depression, obsessive-compulsive disorder (OCD), panic disorder, generalized anxiety disorder (GAD), social anxiety disorder	PGKB	2
Psychiatry	SLOW	Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)	Milnacipran (Savella?)	USE CAUTION due to reduced response 	HTR1A	rs6295 CC genotype	F20, F23, F25, F31, F32, F33, F34, F40, F41, F42, F43, F63, K58	depression, obsessive-compulsive disorder (OCD), panic disorder, generalized anxiety disorder (GAD), social anxiety disorder	PGKB	2
Psychiatry	SLOW	Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)	Reboxetine (Edronax?)	USE CAUTION be alert to ADEs and make necessary dose adjustments	CYP3A4	Poor Metabolizer	F20, F25, F31, F32, F33, F34, F40, F41, F43, F84, F90, G47	Major depression, Pain, Obsessive-compulsive disorder, Attention deficit hyperactivity disorder, Autism, Chronic fatigue syndrome, Depressive Disorder, narcolepsy	Literature	3
Psychiatry	STOP/STOP/STOP UP	Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)	Venlafaxine (Effexor?)	CONSIDER ALTERNATIVES (e.g., citalopram, sertraline)/CONSIDER ALTERNATIVES (e.g., citalopram, sertraline)/CONSIDER ALTERNATIVES (e.g., citalopram, sertraline) or INCREASE DOSE by 150%	CYP2D6	Poor Metabolizer/Intermediate Metabolizer/Ultrarapid Metabolizer	F20, F23, F25, F31, F32, F33, F34, F40, F41, F43, F50, F84, F90	Major depression, Pain, Obsessive-compulsive disorder, Attention deficit hyperactivity disorder, Autism, Chronic fatigue syndrome, Depressive Disorder, narcolepsy, eating disorder	DPWG	1
Psychiatry	SLOW	Serotonin Reuptake Inhibitors/Antagonists	Trazodone (Desyrel?)	USE CAUTION be alert to ADEs and make necessary dose adjustments	CYP3A4	Poor Metabolizer	F20, F25, F31, F32, F33, F34, F40, F41, F43, F84, F90, G47	Major depression, Pain, Obsessive-compulsive disorder, Attention deficit hyperactivity disorder, Autism, Chronic fatigue syndrome, Depressive Disorder, narcolepsy	Literature	3
Psychiatry	DOWN/DOWN/UP	Tetracyclic Antidepressants	Maprotiline	DECREASE DOSE/DECREASE DOSE/INCREASE DOSE	CYP2D6	Poor Metabolizer/Intermediate Metabolizer/Ultrarapid Metabolizer	F20, F25, F31, F32, F33, F34, F40, F41, F43, F84, F90	Major depression, Depressive Disorder	Literature	2
Psychiatry	STOP DOWN/STOP/STOP	Tricyclic Antidepressants	Amitriptyline (Elavil?), Clomipramine (Anafranil?), Doxepin (Silenor?), Imipramine (Tofranil?), Protriptyline (Vivactil?), Trimipramine (Surmontil?)	CONSIDER ALTERNATIVES or DECREASE DOSE by 50%/CONSIDER ALTERNATIVES/CONSIDER ALTERNATIVES	CYP2C19	Poor Metabolizer/Rapid Metabolizer/Ultrarapid Metabolizer	F20, F25, F31, F32, F33, F34, F40, F41, F42, F43, F51, F63, F84, F90	ADHD, Pain, Minor depressive disorder, Depressive Disorder	FDA, CPIC, DPWG	2, 2, 1, 2, 2, 2
Psychiatry	STOP DOWN/DOWN/STOP UP	Tricyclic Antidepressants	Amitriptyline (Elavil?), Clomipramine (Anafranil?), Doxepin (Silenor?), Imipramine (Tofranil?), Protriptyline (Vivactil?), Trimipramine (Surmontil?)	CONSIDER ALTERNATIVES or DECREASE DOSE by 50%/DECREASE DOSE by 25%/CONSIDER ALTERNATIVES or INCREASE DOSE by titrating to a higher target dose in accordance with observed clinical response including symptom improvement and minimal if any side effects	CYP2D6	Poor Metabolizer/Intermediate Metabolizer/Ultrarapid Metabolizer	F20, F25, F31, F32, F33, F34, F40, F41, F42, F43, F51, F63, F84, F90, K58	ADHD, Pain, Minor depressive disorder, Depressive Disorder	FDA, CPIC, DPWG	1, 1, 1, 1, 1, 1
Psychiatry	STOP DOWN/DOWN/STOP UP	Tricyclic Antidepressants	Desipramine (Norpramin?), Nortriptyline (Pamelor?)	CONSIDER ALTERNATIVES or DECREASE DOSE by 50%/DECREASE DOSE by 25%/CONSIDER ALTERNATIVES or INCREASE DOSE by titrating to a higher target dose in accordance with observed clinical response including symptom improvement and minimal if any side effects	CYP2D6	Poor Metabolizer/Intermediate Metabolizer/Ultrarapid Metabolizer	F20, F25, F31, F32, F33, F34, F40, F41, F42, F43, F51, F63, F84, F90, K58	ADHD, Pain, Minor depressive disorder, Depressive Disorder	FDA, CPIC, DPWG	1, 1
Rheumatology	SLOW	Nonsteroidal Antiinflammatory Drugs (NSAIDs)	Flurbiprofen (Ansaid?)	USE CAUTION due to the possibility of high plasma levels resulting from decreased clearance	CYP2C9	Poor Metabolizer	M13, M15, M16, M17, M18, M19	osteoporosis	FDA	1
Smoking Cessation	SLOW/SLOW	Smoking Cessation Aids	Bupropion (Zyban?)	USE CAUTION due to reduced effectiveness/USE CAUTION due to reduced effectiveness	ANKK1	A1 Homozygous/A1 Heterozygous	F17	Tabacco Use Disorder	PGKB	2
Smoking Cessation	GO	Smoking Cessation Aids	Nicotine (Nicoderm?)	NORMAL DOSE may have an increased likelihood of smoking cessation and decreased risk of relapse 	COMT	MET Homozygous	F17	Tabacco Use Disorder	PGKB	2
Supplements	STOP/STOP	Vitamins	Folic Acid	CONSIDER ALTERNATIVES (e.g., supplements containing methylfolate) due to reduced folic acid conversion/CONSIDER ALTERNATIVES (e.g., supplements containing methylfolate) due to significantly reduced folic acid conversion	MTHFR	C677T Heterozygous Mutation/C677T Homozygous Mutation	D52, F20, F25, F31, F32, F33, F34, F40, F41, F43, F84, F90		PGKB	2
Toxicology	SLOW/SLOW	Antidotes	Ethanol	USE CAUTION due to increased risk for alcoholism/USE CAUTION due to increased risk for alcoholism	ANKK1	A1 Homozygous/A1 Heterozygous	F10	Alcoholism	PGKB	2
Toxicology	SLOW	Antidotes	Ethanol	USE CAUTION due to increased severity of intoxication and an increased response 	OPRM1	rs1799971 G Allele Carrier	F10	Alcoholism	PGKB	2
Toxicology	SLOW	Antidotes	Methylene Blue (Provayblue?)	USE CAUTION due to risk of hemolytic anemia	G6PD	G6PD Deficiency	D74	methemoglobinemia	FDA, EMA, PMDA	1
Toxicology	STOP	Antidotes	Sodium Nitrite 	CONSIDER ALTERNATIVES	G6PD	G6PD Deficiency			FDA	1
Urology	SLOW	Alpha 1 Blockers	Dutasteride/Tamsulosin (Jalyn?), Tamsulosin (Flomax?)	USE CAUTION due to a marked increase in drug exposure 	CYP2D6	Poor Metabolizer	N32, N40, N41	benign prostatic hyperplasia; urination problem	AIBiotech	1, 1
Urology	SLOW	Alpha 1 Blockers	Silodosin (Rapaflo?)	USE CAUTION due to a marked increase in drug exposure	CYP3A4	Poor Metabolizer	N32, N40, N41	benign prostatic hyperplasia; urination problem	Literature	3
Urology	SLOW	Anticholinergic Agents	Darifenacin (Enablex?), Fesoterodine (Toviaz?)	USE CAUTION when taking CYP3A4 inhibitors due to greater exposure of the drug	CYP2D6	Poor Metabolizer	N23, N32, N39, N40, R30, R32, R35, R39	an overactive bladder; incontinence; frequence urination	FDA, EMA, PMDA, HCSC	1, 1
Urology	SLOW	Anticholinergic Agents	Tolterodine (Detrol?)	USE CAUTION due to a greater chance of seeing cardiac problems from long QT 	CYP2D6	Poor Metabolizer	N23, N32, N39, N40, R30, R32, R35, R39	an overactive bladder; incontinence; frequence urination	FDA	1
